Bremelanotide Acetate

HOUSTON--(BUSINESS WIRE)--SynergenX, alongside its affiliated brands Low T Center and HerKare, today announced the launch of an expanded range of treatment options designed to give patients more flexibility, more choice, and more control over their care. These new offerings will be available across all clinic locations and through select telehealth services as of April, 2026. The expanded lineup introduces new ways to address some of the most common concerns patients face, including low libido, hair loss, low testosterone, and weight management. New options include PT-141, an FDA-approved peptide therapy that supports libido in women; Minoxidil, an FDA-approved treatment for hair restoration; and Enclomiphene Citrate, an oral therapy that helps increase testosterone levels while preserving fertility. Patients will also have access to Sildenafil ODT and Tadalafil ODT, which use FDA-approved active ingredients to support sexual performance with both short-acting and longer-duration options. Additional offerings include oral weight management treatments such as Semaglutide ODT and GLP-1/GIP ODT therapies. Wellness-focused treatments, including Vitamin D injections and Glutathione, are also available to support overall health, recovery, and immune function. Together, these options create more personalized starting points for patients, including non-injection and non-hormonal approaches for those who may not be ready for traditional hormone therapy, allowing more patients to feel great, look great, and live their best lives. “Our goal is simple: to do all we can to help patients feel like themselves again,” said Wayne Wilson, Founder and Chief Executive Officer of SynergenX. “By expanding the ways patients can begin treatment, we’re making care more approachable, more personalized, and easier to fit into everyday life.” All treatments are delivered within a provider-led model that includes comprehensive testing, individualized treatment plans, and ongoing medical oversight. Patients can choose in-clinic care or convenient at-home options, depending on their needs. This expansion reflects SynergenX’s continued commitment to meeting patients where they are and supporting long-term health, confidence, and quality of life. For more information or to schedule a consultation, visit SynergenX.com.

Sprout joins the ranks of biotech's biggest names following record-setting growth, expanding prescriber adoption, and increasing payer coverage RALEIGH, N.C., April 29, 2026 /PRNewswire/ -- TIME has named Sprout Pharmaceuticals among just 10 organizations globally shaping the future of health and life sciences. This recognition follows a defining period of momentum for Sprout and its flagship treatment, Addyi. In December 2025, the U.S. Food and Drug Administration approved an expanded indication for Addyi to include all women under 65 with Hypoactive Sexual Desire Disorder (HSDD), regardless of menopausal status, unlocking a significantly broader patient population and accelerating commercial expansion. Continue Reading Sprout has scaled Addyi into a nationally recognized brand with record-setting commercial growth, expanded prescriber adoption with 1000 new prescribers added each month and increased affordability and access. Addyi is now the #1 prescribed treatment* for frustrating low libido, women's most common sexual concern, and is backed by more than ten years of clinical and real-world patient data. TIME evaluated companies based on impact, innovation, ambition, and success—selecting just 10 companies in health and life sciences as industry leaders. Sprout now stands alongside global powerhouses like Novo Nordisk and Genentech, a reflection of both its operating performance and its role in expanding the boundaries of modern healthcare. "We built this company to challenge a system that told women to settle," said Cindy Eckert, Founder and CEO of Sprout Pharmaceuticals, "To now be recognized by TIME alongside the biggest forces in biotech is proof of what we've always believed - that when you refuse to accept the status quo, you don't just join the industry, you change it." A special print issue featuring all TIME100 Companies Industry Leaders will be available on newsstands April 28. The full list is available now at: Press Contact: Sunshine Sachs Morgan & Lylis [email protected] About Sprout Pharmaceuticals Sprout Pharmaceuticals is leading a revolution in women's health, pioneering innovative treatments that address long-overlooked needs. With the launch of Addyi, the first ever FDA-approved treatment for Hypoactive Sexual Desire Disorder (HSDD), Sprout helped shift the conversation around women's sexual wellness. The company remains committed to advancing science, expanding access, and advocating for the care women deserve. About Addyi® (flibanserin) Addyi is the first FDA-approved prescription medication for the treatment of hypoactive sexual desire disorder (HSDD), now including all women under 65. It is a non-hormonal, once-daily pill prescribed by more than 30,000 U.S. healthcare professionals. Addyi is believed to work on key neurotransmitters involved in sexual desire and responsiveness although the exact mechanism of action of Addyi is unknown. Please see below for the indicated use of Addyi and Important Safety Information including important warnings regarding low blood pressure and fainting. Addyi is broadly accessible and affordable for most patients: women with insurance typically pay just $20 monthly, and for those paying cash, Addyi is available for $149 per month with free shipping through PHILRx mail-order pharmacy. Addyi is also available at more than 70,000 retail pharmacies nationwide, where patients can use a GoodRx coupon to lower out-of-pocket costs. Patients should consult with their healthcare provider to determine whether Addyi is appropriate for them. Learn more or start a telehealth visit today at Addyi.com. About Hypoactive Sexual Desire Disorder (HSDD) Hypoactive Sexual Desire Disorder (HSDD), also known as frustrating low libido, is a persistent lack of sexual interest or desire. It is the most common form of sexual dysfunction in women, impacting an estimated 40% of women according to the Mayo Clinic. What is ADDYI? ADDYI is a prescription medicine used to treat hypoactive (low) sexual desire disorder (HSDD) in women <65 years of age who have not had problems with low sexual desire in the past, no matter the type of sexual activity, situation, or sexual partner, and it is troubling to them. Their low sexual desire is not due to a medical or mental health problem, problems in the relationship, medicine or other drug use. ADDYI is not for use in men or to improve sexual performance. IMPORTANT SAFETY INFORMATION What is the most important information I should know about ADDYI? ADDYI can cause severe low blood pressure and fainting (loss of consciousness). Your risk is higher if you drink alcohol close to your dose. Do not take ADDYI with certain medicines or if you have liver problems. To lower your risk of low blood pressure and fainting: Do not drink alcohol close to the time you take ADDYI. Skip your dose if you had 3 or more drinks before bedtime. Wait at least 2 hours after 1–2 alcoholic drinks before taking ADDYI. After taking ADDYI, do not drink alcohol until the next day Talk to your doctor about the medicines and supplements you take and before starting any new ones Do not take ADDYI if you have liver problems If you feel dizzy or lightheaded after taking ADDYI, lie down right away. Get medical help if symptoms do not go away. Who should not take ADDYI? Do not take ADDYI if you: take certain medicines that increase ADDYI levels in your blood (including some treatments for HIV, fungal infections, antibiotics, hepatitis C, heart conditions, or depression such as nefazodone) have liver problems are allergic to ADDYI What should I tell my doctor before taking ADDYI? Tell your doctor about all your medical conditions, including if you: drink alcohol, use drugs, or have a history of substance abuse have ever had depression or other mental health conditions have low blood pressure or a condition that can cause it are pregnant, planning pregnancy, or breastfeeding Tell your doctor or pharmacist about all medicines and supplements you take, as they may interact with ADDYI. What should I avoid while taking ADDYI? Do not drink alcohol close to your dose Do not drive or operate machinery for at least 6 hours after taking ADDYI Do not drink grapefruit juice Do not take supplements such as St. John's Wort, ginkgo, or resveratrol, or certain medicines like cimetidine, without talking to your doctor What are the possible side effects of ADDYI? ADDYI can cause serious side effects, including: See "What is the most important information I should know about ADDYI?" Sleepiness low blood pressure and fainting The most common side effects include: dizziness nausea tiredness trouble sleeping dry mouth This is not a complete list of side effects. Call your doctor for medical advice. See Full Prescribing Information and Medication Guide, including important warnings regarding low blood pressure and fainting at Addyi.com/pi. * IQVIA Monthly Total Prescriptions Volume Data Comparing Addyi vs Vyleesi in the US. Sept 2022–March 2026 SOURCE Sprout Pharmaceuticals 21% more press release views with Request a Demo